{"analyses":[{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.92","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0049","paramType":"Hazard Ratio (HR)","paramValue":"0.76","statisticalComment":"The Log-Rank Test was stratified by etiology of disease, geo. region, presence of extrahepatic spread of disease and/or macrovascular invasion.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.1","upperLimit":"12.0","value":"10.2"},{"groupId":"OG001","lowerLimit":"6.8","upperLimit":"9.4","value":"8.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"470"},{"groupId":"OG001","value":"237"}],"units":"Participants"}],"description":"The primary analysis of OS is defined as the time from randomization to death from any cause. The analysis was based on a second planned interim analysis prespecified to be performed at approximately the 75% information fraction (ie, at approximately 466 deaths). The data cutoff date for this event-driven analysis in the Intent to Treat (ITT) population was 01 June 2017. Median OS was calculated using the Kaplan-Meier estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cabozantinib (XL184) 60 mg tablet once daily\n\nCabozantinib tablets","id":"OG000","title":"Cabozantinib (XL184)"},{"description":"Oral cabozantinib-matched placebo tablet once daily\n\nPlacebo tablets","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"The ITT population was used and included 707 randomized subjects (470 cabozantinib, 237 placebo) in the second interim analysis with a cutoff date of 01 June 2017.","reportingStatus":"POSTED","timeFrame":"Up to 45 months","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}